Overview

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Status:
Not yet recruiting

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

Phase:

Phase 2

Details

Lead Sponsor:

Yonsei University

Treatments:

Nivolumab